

Supplementary Table 3. Clinical Characteristics of Patients with Persistent MRSA Bacteremia Who Underwent Antimicrobials Switching during the Course of Therapy and Those who Did Not

Variable	Overall (n=116)	With change (n=43)	Without change (n=73)	p value
Sex, male	60 (51.7)	20 (46.5)	40 (54.8)	0.389
Age (yr)	69 (58.25–81)	71 (61–81)	67 (58–79)	0.455
Vancomycin MIC \geq 1 mg/L	73 (62.9)	33 (76.7)	40 (54.8)	0.018
Initial treatment				
Definitive antimicrobial agents				0.022
Vancomycin	98 (84.5)	32 (74.4)	66 (90.4)	
Teicoplanin	18 (15.5)	11 (25.6)	7 (9.6)	
Beta-lactams co-administration	71 (61.2)	25 (58.1)	46 (63.0)	0.603
Time to active antibiotics (days)*	2 (1–3)	2 (1–3)	2 (1–2.5)	0.506
Initial laboratory findings				
White blood cell count (/ μ L)	12940 (10570–18080)	12380 (10560–14810)	13610 (10490 – 19110)	0.143
C-reactive protein (mg/dL)	19.38 (6.62–26.75)	22.30 (8.78–27.50)	18.24 (6.01–26.42)	0.293
Disease severity				
ICU admission within 24 hours*	50 (43.1)	16 (37.2)	34 (46.6)	0.325
Pitt bacteremia score (initial)	2 (1–3)	1 (0–3)	2 (1–3.5)	0.112
Pitt bacteremia score (day 4)*	1 (0–3)	0 (0–2)	1 (0–4)	0.055
Focus of infection				
Endocarditis	14 (12.1)	6 (14.0)	8 (11.0)	0.633
Osteoarticular focus	29 (25.0)	13 (30.2)	16 (21.9)	0.318
Pneumonia	10 (8.6)	1 (2.3)	9 (12.3)	0.089
Surgical wound infection	2 (1.7)	1 (2.3)	1 (1.4)	>0.999
Skin and soft tissue infection	12 (10.3)	6 (14.0)	6 (8.2)	0.357
Intravascular catheter	24 (20.7)	7 (16.3)	17 (23.3)	0.368
Unknown focus	21 (18.1)	6 (14.0)	15 (20.5)	0.373
Metastatic infection	33 (28.4)	15 (34.9)	18 (24.7)	0.238
Echocardiography	83 (71.6)	36 (83.7)	47 (64.4)	0.026
Onset of bacteremia				
Hospital-acquired	63 (54.3)	22 (51.2)	41 (56.2)	
Healthcare-associated	28 (24.1)	12 (27.9)	16 (21.9)	
Community-acquired	25 (21.6)	9 (20.9)	16 (21.9)	
Bacteremia duration (days)	6 (3–12)	11 (6–19)	5 (3–8)	<0.001
Prostheses				
Orthopedic device	21 (18.1)	8 (18.6)	13 (17.8)	0.914
Cardiovascular device	4 (3.4)	2 (4.7)	2 (2.7)	0.626
Long-term CVC	25 (21.6)	8 (18.6)	17 (23.3)	0.554
Removal of eradicable focus				
No removal	31 (26.7)	15 (34.9)	16 (21.9)	0.464
Non-eradicable	49 (42.2)	15 (34.9)	34 (46.6)	
Removal of focus after day 3*	12 (10.3)	4 (9.3)	8 (11.0)	
Removal of focus before day 3*	24 (20.7)	9 (20.9)	15 (20.5)	
Charlson comorbidity index	2 (1–4)	1 (0–4)	2 (1–5)	0.043
Immunosuppression	21 (18.1)	7 (16.3)	14 (19.2)	0.695
ID consultation within 7 days*	75 (64.7)	32 (74.4)	43 (58.9)	0.091

MRSA, methicillin-resistant *Staphylococcus aureus*; CVC, central venous catheter; ICU, intensive care unit; ID, infectious diseases; IQR, interquartile range; HR, hazard ratio; CI, confidence interval.

Data are presented as numbers (%) or median (interquartile range) unless otherwise indicated.

*Time points were calculated from the onset of bacteremia.